Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

3 Important Catalysts That Fueled Repligen in 2013
Motley Fool
Thursday, December 12, 2013 - 8:42am
tags:
Repligen, Orencia, Bristol-Myers Squibb, monoclonal antibodies
Synta Pharmaceuticals announces interim results from ENCHANT-1 Ganetespib trial
Yahoo/Fly on the Wall
Thursday, December 12, 2013 - 8:38am
tags:
Synta Pharmaceuticals, ganetespib, metastatic breast cancer
FDA approves 6 low-cost versions of blockbuster antidepressant pill Cymbalta
Yahoo/AP
Thursday, December 12, 2013 - 7:16am
tags:
FDA, patents, antidepressants, Cymbalta, Eli Lilly
Bristol adds medicine to patent pool for AIDS drugs
Yahoo/Reuters
Thursday, December 12, 2013 - 6:50am
tags:
AIDS, HIV, Bristol-Myers Squibb, patents, Reyataz
GSK announces study shows FluLaval vaccine effective in preventing flu in kids
Yahoo/Fly on the Wall
Thursday, December 12, 2013 - 6:49am
tags:
GSK, Flulaval Quadrivalent, vaccines, Flu
FDA panel backs allergy drug of France's Stallergenes
Yahoo/Reuters
Thursday, December 12, 2013 - 6:49am
tags:
FDA, France, Stallergenes, Oralair, advisory panels, grass pollen allergy
Savient attracts a buyer willing to get it out of bankruptcy court
Fierce Pharma
Wednesday, December 11, 2013 - 2:46pm
tags:
Savient, M&A, Krystexxa, Crealta Pharmaceuticals
Novartis: 2 Novel Cancer Therapies Show Promising Results
Seeking Alpha
Wednesday, December 11, 2013 - 2:42pm
tags:
Novartis, Celgene, JNJ, Merck, panobinostat, Multiple Myeloma, acute lymphocytic leukemia
Stomach acid drugs may increase vitamin deficiency risk
Reuters
Wednesday, December 11, 2013 - 12:11pm
tags:
PPIs, H2RAs, Prevacid, Prilosec, Nexium, Tagamet, Zantac, GSK, Boehringer Ingelheim, P&G, AstraZeneca, Takeda
FDA to phase out some antibiotic use in animal production
Reuters
Wednesday, December 11, 2013 - 11:45am
tags:
FDA, antibiotics, animal health, Zoetis, Eli Lilly
Task Force: Ban Sales Reps From Academic Medical Centers
Pharmalot
Wednesday, December 11, 2013 - 11:44am
tags:
drug reps
Orexigen Resubmits Contrave New Drug Application
Yahoo
Wednesday, December 11, 2013 - 11:25am
tags:
Orexigen, FDA, obesity, Contrave
Supreme Court declines to hear Arthrex appeal of its $85 million patent infringement loss to Smith & Nephew
Mass Device
Wednesday, December 11, 2013 - 11:25am
tags:
Supreme Court, devices, Arthrex, patents, Smith & Nephew, surgical anchors
Boston Scientific May Face A Tough FDA Panel
Forbes
Wednesday, December 11, 2013 - 11:23am
tags:
Boston Scientific, FDA, advisory panels, devices, WATCHMAN, atrial fibrillation
ImmunoCellular's ICT-107 Phase II: Patience Will Pay Off
Seeking Alpha
Wednesday, December 11, 2013 - 11:21am
tags:
ImmunoCellular Therapeutics, ICT-107, glioblastoma multiforme
Cancer drug test results send CytRx shares soaring by 75%
Marketwatch
Wednesday, December 11, 2013 - 11:11am
tags:
CytRx, aldoxorubicin
3 Drugmakers to Watch in the New Year
Motley Fool
Wednesday, December 11, 2013 - 11:10am
tags:
pimavanserin, Acadia, Zerenex, Keryx, Iclusig, Ariad Pharmaceuticals
Agios advances cancer metabolism collaboration with Celgene
Yahoo/Fly on the Wall
Wednesday, December 11, 2013 - 9:35am
tags:
Agios Pharmaceuticals, Celgene, cancer metabolism
A Look Back at Immunomedics' Volatile but Rewarding 2013
Motley Fool
Wednesday, December 11, 2013 - 9:32am
tags:
Immunomedics
What Is Johnson & Johnson's Opportunity In Hepatitis C Market?
Forbes
Wednesday, December 11, 2013 - 9:01am
tags:
JNJ, hepatitis C, Olysio

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.